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Background: Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue.
Methods: We examined the correlation of panitumumab (an anti-epidermal growth factor [EGFR] antibody) tumor
penetration and EGFR saturation, a potential obstacle in large molecule drug delivery, using pharmacokinetics,
pharmacodynamics, and tumor growth rate in an A431 epidermoid carcinoma xenograft model of human cancer.
To determine receptor saturation, receptor occupancy, and levels of proliferation markers, immunohistochemical
and flow cytometric methods were used. Pharmacokinetic data and modeling were used to calculate growth
characteristics of panitumumab-treated tumors.
Results: Treatment with panitumumab in vivo inhibited pEGFR, Ki67 and pMAPK levels vs control. Tumor
penetration and receptor saturation were dose- and time-dependent, reaching 100% and 78%, respectively.
Significant tumor inhibition and eradication (p< 0.05) were observed; plasma concentration associated with tumor
eradication was estimated to be 0.2 μg/ml. The tumor inhibition model was able to describe the mean tumor
growth and death rates.
Conclusions: These data demonstrate that the antitumor activity of panitumumab correlates with its ability to
penetrate into tumor tissue, occupy and inhibit activation of EGFR, and inhibit markers of proliferation and MAPK
signaling.
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Solid tumors differ from the normal tissue from which
they were derived with respect to their vasculature,
interstitial fluid pressure, lymphatic drainage, cell dens-
ity, and extracellular matrix components [1]. This com-
plex physiologic barrier can be especially challenging for
large molecule therapeutics, such as targeted monoclo-
nal antibodies. The intrinsic properties of antibodies
such as the size of the therapeutic and affinity for the
target may further hinder penetration into the tumor tis-
sue. These properties must be balanced with the* Correspondence: radinsky@amgen.com
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reproduction in any medium, provided the oraffinities of its competing ligands and the pharmacoki-
netic properties that result in clinically feasible dosing
schedules [2,3].
Understanding the relationship among pharmacoki-
netic, pharmacodynamic, and anti-tumor parameters is
critical for the development of an oncology therapeutic.
It allows for the proper selection of dose and schedule of
the molecule and the potential development of a clinic-
ally applicable marker of target coverage. Clinically,
these correlations have proven to be challenging with
the early small molecule tyrosine kinase inhibitors (SM
TKIs) because of the variability in plasma and tumor ex-
posure in patients and lack of biochemical coverage
markers [4,5]. Although targeted monoclonal antibodyal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ing half-lives, greater affinity and selectivity, and limited
off-target toxicity compared with SMTKIs, one obstacle
is achieving adequate exposure in solid tumors [3].
The epidermal growth factor receptor (EGFR) is a
tyrosine kinase (TK) transmembrane receptor that is
constitutively expressed in tissues of epithelial origin and
is overexpressed in a variety of solid tumors including
colorectal carcinoma, non-small cell lung carcinoma,
renal cell carcinoma, ovarian, head and neck, prostate,
breast, and pancreatic carcinomas [6,7]. Activation of
the EGFR by EGF-like ligands mediates the Ras/Raf/
MAPK, STAT and PI3K/AKT signaling pathways, which
results in phenotypic changes including increased cellu-
lar proliferation, adhesion, migration, angiogenesis, and
survival [8-10]. Furthermore, elevated expression of
EGFR and its ligands have been found to be associated
with poor clinical prognosis in several tumor types of
epithelial origin [6,11,12].
Panitumumab is a fully human monoclonal antibody
that binds EGFR with high affinity (5x10-11 M), prevents
ligand-induced activation of all EGF-like ligands and
production of angiogenic factors, and arrests tumor cell
proliferation [13,14]. In preclinical studies, panitumu-
mab treatment resulted in inhibition of tumor growth
and eradication of tumors in some animal models
[13,15,16]. Because panitumumab is a monoclonal anti-
body, it may have greater specificity for the EGFR com-
pared with SM TKIs, which can cross-react with other
relevant kinases [17]. Further, because panitumumab is
fully human, it may also result in fewer immunogenic
reactions in patients compared with chimeric or huma-
nized EGFR monoclonal antibodies [13,15]. In clinical
studies, panitumumab has demonstrated antitumor ac-
tivity and a tolerable safety profile in colorectal cancer as
a monotherapy and in combination with standard of
care chemotherapeutics [18-20]. Selection based on
tumor KRAS status has further increased the benefit of
the patients treated with panitumumab [18,19,21,22].
To date, the extent of tumor penetration by panitumu-
mab and its correlation with pharmacodynamic and
antitumor activity has not been reported. Here, we
investigated the correlation of serum levels of panitumu-
mab, receptor occupancy of the EGFR, and inhibition of
EGFR signaling with inhibition of cellular proliferation




Six- to 10-week-old female CD1 nude mice (Charles Riv-
ers Laboratories, Raleigh, NC) were used in all studies.
Mice were housed in sterilized cages, 5 mice per cage,
and were supplied ad libitum with Harlan TekladSterilized rodent diet 8656 and reverse-osmosis water
from the institutional water supply system. Room
temperature was maintained between 68–72° F, and rela-
tive humidity was maintained between 34 and 73%. The
institutional laboratory housing the cages provided a 12-
hour light cycle and met all Association for Assessment
and Accreditation of Laboratory Animal Care (AAA-
LAC) specifications.
A431 epidermoid carcinoma cells (American Type
Culture Collection, Manassas, VA) were cultured in 10%
fetal bovine serum (FBS)/RPMI to 80% confluency and
harvested prior to injection. Mice were injected subcuta-
neously with 0.2 ml of 1 × 107 A431 cells suspended in
non-serum containing RPMI media into the left flank.
Nine days following injection, mice were treated intra-
peritoneally with either panitumumab (5, 20, 200, or
500 μg), PBS vehicle control, or control IgG2 (500 μg)
twice weekly. Tumor volumes, calculated as length ×
width × height in mm3, and body weights were recorded
at regular intervals. Results were expressed as the
mean ± standard error (SE). The data were statistically
analyzed with factorial ANOVA followed by Scheffe's
post hoc analysis for repeated measurements (StatView
v5.0.1, SAS Institute). Mice were euthanized with CO2
asphyxiation, and for histological analysis, some tumors
were harvested, immersion fixed, and embedded in par-
affin using standard techniques. All experiments were
conducted in accordance with institutional guidelines
and under an Institutional Animal Care and Use Com-
mittee (IACUC) protocol.
Immunoprecipitation and phosphorylation of EGFR
To assess EGFR phosphorylation in vitro, A431 carcin-
oma cells (80% confluent) were incubated in 0.5% FBS
for 16 hours prior to treatment. Cells were treated with
a control IgG2 antibody (10 μg/mL) or panitumumab
(0.5, 2, and 10 μg/mL) for 60 minutes, followed by a 15-
minute incubation with or without EGF (100 ng/mL).
Cells were then washed three times in cold PBS and
scraped in RIPA Buffer (20 mM Tris–HCl pH 7.5, 1%
Igepal, 1% sodium deoxycholate, 150 mM NaCl, 0.1%
SDS, 1% Triton X-100, pH 7.6). To measure EGFR phos-
phorylation in vivo, CD1 nude mice bearing A431 xeno-
graft tumors of approximately 300 mm2 received
intraperitoneal injections of either 1 mg of panitumu-
mab or IgG2 control at both 24 hours and 4 hours prior
to receiving 100 μg of EGF intravenously for 30 minutes.
Tumors were excised and washed three times in cold
PBS, and cell extracts were prepared in RIPA lysis buffer.
EGFR was immunoprecipitated using an anti-EGFR
monoclonal antibody clone, EGFR.1 (Ab-3 Labvision,
Fremont, CA), in 500 μg of total cell extract. Phosphor-
ylation of immunoprecipitated EGFR protein was then
determined by immunoblot with an antiphosphotyrosine
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ogy, Beverly, MA). Immunoprecipitated EGFR was
detected by immunoblot using an anti-EGFR antibody
(#2232, Cell Signaling Technology, Beverly, MA).
Pharmacokinetics
Serum samples for measuring panitumumab concentra-
tion for intraperitoneal doses administered (20, 200, or
500 μg) were collected postdose on 1, 2, 3, 4, 7, and
14 days after the initial dose and analyzed using an elec-
trochemiluminescence (ECL) assay. Panitumumab in
serum samples was captured using a biotinylated anti-
idiotypic antibody to panitumumab immobilized on
streptavidin-coated magnetic beads. This antibody was
generated as described previously [23]. Panitumumab
was detected with a ruthenium-labeled panitumumab
anti-idiotypic antibody. ECL counts, which were directly
proportional to panitumumab concentration, were mea-
sured with an IGEN M8 Analyzer (IGEN International
Inc., Gaithersburg, MD). The observed serum panitumu-
mab concentrations were analyzed using a compartmen-
tal approach. Because panitumumab does not bind
mouse EGFR, EGFR-mediated clearance in mice is lim-
ited, and consequently, an open two-compartment PK
model with first-order absorption from the site of ad-
ministration and first-order elimination from the central
compartment was fit to the observed panitumumab
serum concentrations [13].
Tumor penetration
A431 tumor xenografts from animals receiving control
IgG2 antibody (500 μg) or panitumumab at doses of 20,
200, or 500 μg twice weekly were collected on days 1
and 4, fixed in IHC Zinc fixative (BD Pharmingen, San
Diego, CA), and embedded in paraffin using standard
techniques. Unstained 5 μm-thick tissue sections were
deparaffinized, hydrated, and incubated with 20 μg/mL
of an anti-idiotype antibody that specifically detects
panitumumab (Amgen Inc., Thousand Oaks, CA) in
DAKO antibody Diluent (DAKO, Carpinteria, CA) for
30 minutes. Slides were then incubated and labeled with
1:250 (2.4 μg/ml) alkaline phosphatase (AP)-conjugated
goat anti-mouse antibody (Jackson ImmunoResearch La-
boratories, West Grove, PA). AP Blue Substrate (Vector
Labs, Burlingame, CA) was used to visualize the anti-
idiotype antibody in the tumor samples. The EGFR
pharmDx™ diagnostic kit (DAKO, Carpinteria, CA) was
used to concurrently detect EGFR. Slides were quenched
with 3% hydrogen peroxide, incubated with mouse anti-
EGFR, and labeled with horseradish peroxide-conjugated
dextran polymer. The red chromagen AEC (3-amino-9-
ethylcarbazole; Vector Labs, Burlingame, CA) was used
to visualize EGFR staining. Membrane staining intensity
was graded by visual qualitative estimation of theamount of blue chromagen staining for panitumumab in
tumor tissue compared with the intensity of red chroma-
gen staining for EGFR. Tumor penetration was defined
as the time and extent to which panitumumab enters
into the tumor tissue.
Saturation
The saturation level of EGFR by panitumumab was
determined by flow cytometry on A431 epidermoid
carcinoma cells. A431 cells were incubated in vitro
with increasing concentrations of unlabeled panitumu-
mab and phycoerythrin (PE)-labeled panitumumab
(Invitrogen, Carlsbad, CA). Panitumumab was labeled
with R-phycoerythrin (PE) and used at the lowest concen-
tration required to achieve cell-surface binding saturation
(1 μg/mL or 6.8 nM). Mouse anti-human EGFR monoclo-
nal antibody (clone Ab-3 at 1 μg/ml; Labvision, Fremont,
CA) was labeled with anti-mouse IgG-Alexa 488 and used
to measure total EGFR expression on tumor cells. This
antibody does not share the same epitope as panitumu-
mab. A standard binding saturation curve was gener-
ated for using A431 cells grown in vitro. A431 cell
suspensions were incubated with control human IgG2
or unlabeled panitumumab at 0, 0.21, 0.63, 1.83, 5.64,
or 17 nM to compete with PE-labeled panitumumab
kept constant at 6.8 nM. Simultaneously, cells were
incubated with Alexa 488-labeled mouse anti-human
EGFR antibody (Ab-3) at 6.8 nM for 1 hour in binding
media (2% FBS, 1% normal rabbit serum, 10% normal
goat serum, 0.1% sodium azide in PBS). Cells were
analyzed for binding of PE-labeled panitumumab and
Alexa 488-labeled anti-EGFR antibody (Ab-3) by
2-color flow cytometry using FACSCalibur (Becton
Dickinson, Franklin Lakes, NJ). The ratiometric meas-
ure of bound PE-labeled panitumumab to total EGFR
expression was calculated and normalized to 100%
based on the standard saturation curve results. The
standard curve was used to determine panitumumab-
bound EGFR saturation. A decrease in the level of
bound PE-labeled panitumumab as compared to total
EGFR expression served as an indicator of bound un-
labeled panitumumab. The relationship between EGFR
saturation and panitumumab concentration were fitted
to a hyperbolic Emax model to determine Kd values.
For in vivo panitumumab EGFR saturation analyses,
tumor samples were collected from mice bearing A431
tumor xenografts treated with 500 μg of either panitu-
mumab or control IgG2 antibody twice a week on days
0, 3, and 7. Tumor cell suspensions were extracted from
individual tumor xenograft samples and resuspended by
mincing the tumor pieces in a digestion buffer (collagenase
200 U/ml, DNAse 1500 U/ml, hyaluronidase 300 U/ml,
and dispase 1 U/ml) for 20 minutes at 37° C. The iso-
lated tumor cells were incubated with Alexa 488-
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PE-labeled panitumumab at 6.8 nM each. The level of
total EGFR expression and bound panitumumab was
determined by flow cytometry as described above for
A431 cells grown in vitro. Individual A431 tumor sam-
ples from 3 mice for each time point were analyzed and
the standard error of the mean was provided.
Immunohistochemistry
For the intracellular proliferation and signaling markers
MIB-1 (Ki67) and phospho-MAPK (pMAPK), respect-
ively, 5-μm-thick tissue sections were deparaffinized and
hydrated. Slides were pretreated with Antigen Retrieval
Citra (BioGenex, San Ramon, CA), then blocked with
CAS Block (Zymed Laboratories, Inc., South San Fran-
cisco, CA) for 10 minutes. For Ki67, tissue sections were
incubated for 1 hour with rabbit polyclonal anti-Ki67
(Novo Castra Laboratories Ltd., Newcastle upon Tyne,
UK) at a dilution of 1:2000 followed by detection using
biotinylated goat anti-rabbit immunoglobulin (Vector
Laboratories, Burlingame, CA). pMAPK-blocked sec-
tions were incubated with rabbit polyclonal anti-
phospho-p44/42 MAPK (Thr202/Tyr204; Cell Signaling
Technology, Beverly, MA) at a dilution of 1:50, followed
by detection using HRP-conjugated goat anti-rabbit anti-
body (Jackson ImmunoResearch Laboratories, West
Grove, PA) at a dilution of 1:500. Slides were quenched
with 3% hydrogen peroxide and followed with Avidin-
Biotin Complex (Vector Laboratories, Burlingame, CA).
Reaction sites were visualized with DAB (DAKO Corp.,
Carpinteria, CA) and the slides were counterstained with
hematoxylin.
Modeling tumor growth in an A431 carcinoma xenograft
model
Tumor growth data were modeled using a modified ver-
sion of the model proposed by Simeoni [24]. In the ab-
sence of treatment, tumor cells were assumed to
proliferate at a constant rate. In the presence of panitu-
mumab, an Emax model assumes that the concentration
at the tumor induces damage in some cells eventually
leading to cell death. In this model, Emax is the max-
imum cell death rate induced by blocking EGFR andEGF (100 ng/mL)                – + + + +
anti-pTYR
anti-EGFR
Panitumumab (µg/mL)    – – 10 2 0.5
In Vitro A431 cell
Figure 1 Panitumumab inhibited ligand-induced pEGFR in vitro and i
harvested from (A) panitumumab-treated A431 epidermoid carcinoma cells
treated A431 xenograft tumors 30 minutes after an intraperitoneal injectionEC50 is the concentration at the tumor that elicits 50%
of maximum cell death rate. In addition, the concentra-
tion for tumor eradication was estimated from the
model as previously described [24].
Results
Panitumumab inhibits ligand-induced EGFR
phosphorylation in vitro and in vivo
To determine if panitumumab inhibits EGFR activation in
A431 cells in vitro, serum-starved subconfluent cells were
pretreated with panitumumab (or control IgG2) at varying
concentrations and then stimulated with EGF for 15 min-
utes. Panitumumab treatment resulted in a dose-dependent
inhibition of ligand-induced pEGFR (Figure 1A). Increasing
concentrations of panitumumab resulted in a concomitant
reduction in ligand-induced pEGFR at 10 μg/ml detected
by immunoprecipitation and immunoblotting with anti-
pTYR and anti-EGFR antibodies. EGF stimulation reduced
total EGFR levels (Figure 1A).
To test if panitumumab can inhibit EGFR autopho-
sphorylation in vivo, mice bearing A431 xenograft
tumors of approximately 300 mm3 were injected intra-
peritoneally with 1 mg panitumumab or control IgG2 at
0 and 20 hours. Twenty-four hours post injection, mice
were injected intravenously over 30 minutes with 100 μg
EGF. Similar to the in vitro results, treatment with pani-
tumumab resulted in an inhibition of ligand-induced
pEGFR in A431 established tumor xenograft tissue as
detected by immunoprecipitation and immunoblotting
with anti-pTYR and anti-EGFR antibodies (Figure 1B).
Pharmacokinetics of panitumumab in mice
Panitumumab serum concentrations in the A431
xenograft-bearing mice after twice weekly intraperitoneal
administration of panitumumab at 20, 200, and 500 μg
were measured and fit well to the pharmacokinetic model
(Figure 2). The maximum observed concentration (Cmax)
and area under the curve (AUC) after the first dose based
on the modeled curves increased in a dose-proportional
manner. The Cmax increased from 12.2 to 305 μg/mL and
AUC increased from 30.2 to 755 μgday/mL as the dose
increased from 20 to 500 μg/kg. Absorption rate, central
volume of distribution, and systemic clearance wereanti-pTYR
anti-EGFR
In Vivo A431 xenografts
Panitumumab (mg) – – 1
EGF (100 µg) – + +
n vivo. Immunoprecipitation of both phospho- and total- EGFR
in vitro 15 minutes after a treatment with EGF and (B) panitumumab-
of EGF.
Time (day)





























Figure 2 The observed and modeled panitumumab PK profiles
in xenograft mice after intraperitoneal administration of
panitumumab twice a week. Serum concentrations of
panitumumab were assessed 1, 2, 3, 4, 7, and 14 days after the first
dose (symbols, n = 5/time point); lines represent modeled
pharmacokinetic profiles.
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respectively.
Panitumumab penetrates xenograft tissues in a dose- and
time-dependent manner
The ability of panitumumab to penetrate tumors was
investigated in mice bearing A431 xenografts. Animals
bearing established tumors of approximately 300 mm3
were treated with panitumumab at 20, 200, or 500 μg via
intraperitoneal injection. Tumors were harvested and
analyzed for the degree of panitumumab penetration at
24 or 96 hours post injection. Staining for panitumumab
was initially more intense around blood vessels and in
the peripheral regions of the tumor tissue where blood
flow is the highest. Panitumumab staining increased into
the surrounding tissues with increased dose and time. At
24 hours, staining for panitumumab was observed and
the intensity/extent was dose-dependent: ~37% with
20 μg, ~53% with 200 μg, and ~93% with 500 μg
(Figure 3A). At 96 hours, staining became more diffuse
with ~37% staining at 20 μg, ~80% at 200 μg and ~95%
at 500 μg (Figure 3B). Using qualitative immunoreactiv-
ity grading, maximum tumor penetration of greater than
95% was reached with 500 μg of panitumumab after 96
hours (Figure 3C).
Panitumumab saturates EGFR on A431 epidermoid
carcinoma cells in vitro and in vivo
To determine the EGFR saturation (receptor occupancy)
in A431 cells following treatment with panitumumab
in vitro and in vivo, a flow cytometry assay was devel-
oped using a non-competing Alexa 488-labeled mouse
anti-human EGFR antibody and PE-labeled panitumu-
mab. The ratio of Alexa 488-labeled antibody (whichmeasures the total amount of EGFR on A431 cells) com-
pared with PE-labeled panitumumab (which competes
for unlabeled panitumumab) allowed for the determin-
ation of the level of panitumumab-bound EGFR and
hence saturation. The saturation curve showed that a
panitumumab concentration of 6.8 nM was sufficient to
saturate greater than 90% of expressed EGFR on A431
cells in vitro whereas 17 nM was sufficient to saturate
97% (range 95.6 to 98%; Figure 4A). FACS dot plots of
PE-panitumumab vs Alexa-EGFR of A431 cells treated
with control IgG (Figure 4B) or unlabeled panitumumab
(Figure 4C) demonstrated the binding specificity of pani-
tumumab to EGFR.
Using the in vitro standard curve, the EGFR saturation
concentration in vivo was assessed in dissociated cells
from A431 xenografts from mice treated with 500 μg
panitumumab or control IgG2 antibody twice weekly
(Figure 4D). Saturation was assessed on days 1, 3, 4, and
7 after treatment. Administration of panitumumab at
500 μg resulted in the saturation of EGFR expressed in
A431 xenografts in a time-dependent manner, with a
mean saturation of 10% at day 1, 30% at day 3, 22.5% at
day 4, and 78% at day 7 (Figure 4D). The estimated (SE)
Kd value was 0.922 (0.059). Similarly, FACS dot plots of
PE-panitumumab vs Alexa-EGFR of A431 cells treated
with control IgG after 7 days (Figure 4E) or panitumu-
mab after 7 days (Figure 4F) demonstrated the binding
specificity of panitumumab to EGFR in the assay.
Panitumumab reduces markers of proliferation in
established A431 xenografts
Ligand-induced activation of the EGFR can induce cellu-
lar proliferation via the MAPK signaling pathway. To de-
termine if panitumumab can inhibit cellular proliferation
in vivo, mice bearing established A431 tumor xenografts
were treated twice a week for 14 days with 500 μg of ei-
ther panitumumab or IgG control. Fixed tissue sections
were evaluated for levels of cellular proliferation and sig-
naling markers, Ki67 and pMAPK. Panitumumab treat-
ment of A431 xenograft tumors resulted in a reduction
in Ki67 and pMAPK staining compared with the vehicle
control (Figure 5). These data suggest that panitumumab
mediates inhibition of EGFR activity by decreasing cellu-
lar proliferation and downstream MAPK signaling.
Panitumumab inhibits growth of established A431
xenografts in a dose-dependent manner
To determine if tumor penetration, EGFR saturation,
and inhibition of EGFR activation and proliferation cor-
related with anti-tumor activity, mice bearing A431
xenograft tumors of approximately 300 mm3 tumors
were injected intraperitoneally twice a week for 50 days
with PBS, 500 μg of control IgG2 antibody, or 5, 20, 200
or 500 μg of panitumumab (n = 10 animals in each
Image Legend
Red = EGFR staining
Light Blue = Panitumumab
Dark Blue = Anti-Idiotye Ab
Increasing Dose of Panitumumab
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Figure 3 Penetration of panitumumab into tumor xenograft tissue is dose and time dependent. Panitumumab initially surrounded the
afferent blood supply and then penetrated diffusely into the surrounding tumor tissue. A431 tumor xenograft samples of animals receiving 0, 20,
200, or 500 μg panitumumab were collected (A) 24 hours or (B) 96 hours after initiation of dosing and incubated with anti-idiotype IgG2-bound
panitumumab to detect administered panitumumab (blue chromagen) and DAKO anti-EGFR to detect EGFR (red chromagen). Micron
bars = 10 μm all high magnification images and black arrows identify blood vessels. (C) IHC staining intensities for the anti-idiotype IgG2-bound
panitumumab were qualitatively graded and plotted as an estimated percent of total staining intensity.
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resulted in a dose-dependent tumor inhibition at the 5-
and 20-μg doses and in complete tumor eradication at
the 200- and 500-μg doses. Control animals were eutha-
nized on day 22 whereas animals treated withpanitumumab at 5 μg and 20 μg were euthanized on
days 44 and 67, respectively, because of uncontrolled
tumor growth and consistent with IACUC guidelines. In
animals treated with panitumumab at 200 μg and 500
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Figure 4 Treatment with panitumumab resulted in the saturation of EGFR on A431 epidermoid carcinoma cells in vitro and in vivo in
xenograft tumors as determined by flow cytometry. (A) A431 cells were incubated in vitro with increasing concentrations of unlabeled
panitumumab and phycoerythrin (PE)-labeled panitumumab to determine lowest concentration required to achieve cell-surface binding
saturation. (B, C [inset]) FACS dot plots of PE-panitumumab vs Alexa-EGFR of A431 cells treated with 17 nM of either B, control IgG or C,
panitumumab for 1 hour. (D) The percent of EGFR saturation following treatment was determined in vivo by measuring the level of bound
panitumumab on the dissociated tumor xenograft cells by flow cytometry and plotting test results against the standard curve generated in
Figure 4A. (E, F [inset]) FACS dot plots of PE-panitumumab vs Alexa-EGFR of dissociated A431 xenograft cells treated with 500 μg of either E,
control IgG or F, panitumumab; tumor cells were dissociated and assayed 7-days post-treatment.
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300 days after the last dose was administered
(Figure 6A), at which time they were euthanized and no
further data were collected. No difference in the body
weights between the control-treated and panitumumab-
treated animals were observed (data not shown).
The observed tumor growth data from the A431 xeno-
graft study (Figure 6A) were modeled to calculate thegrowth and death rates upon treatment with panitumu-
mab. This model described a mean A431 tumor cell
growth of 3.73 mL/h, which was consistent with the
observed results. Maximum EGFR-mediated tumor cell
death rate was 8.97 h-1 and the steady-state concentra-
tion at the tumor that elicits 50% of maximum cell death
rate was 0.81 μg/mL (Figure 6B). In addition, the con-
centration for tumor eradication, which accounts for
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Figure 5 Markers of proliferation (Ki67) and downstream kinase signaling (pMAPK) in A431 epidermoid carcinoma xenografts were
decreased after treatment with panitumumab. Fixed tissue sections were prepared from A431 xenograft tumors from mice treated with either
500 μg IgG2 control vehicle or 500 μg panitumumab twice a week for two weeks. Qualitative changes in Ki67 or pMAPK immunoreactivity were
visualized with DAB and hematoxylin counterstain. Micron bars = 100 μm for low magnification images on the left and 10 μm for high
magnification images on the right. Representative fields are shown.
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be 0.20 μg/mL.Discussion
The data presented here examined the correlation of
panitumumab tumor penetration and EGFR saturation,
a potential obstacle in drug delivery of large molecules
in treating solid tumors, using pharmacokinetics,
pharmacodynamics, and anti-tumor activity in an A431
epidermoid carcinoma xenograft model system.One important factor that leads to the clinical efficacy
of a therapeutic is its ability to modulate the target for
which it is intended. Although A431 cells express ap-
proximately 1.2 million EGFRs per cell [13], there is only
a minimal amount of basal phosphorylation of the EGFR
in vitro or in vivo (Figure 1). Therefore, to address pani-
tumumab target coverage, we employed an inhibition of
ligand-induced phosphorylation assay. Panitumumab
treatment inhibited EGFR autophosphorylation in A431
cells in vitro in a dose-dependent manner as well as
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Panitumumab 500 µg ip 2x/wk
Figure 6 Observed and model-fitted tumor growth curves in an A431 carcinoma xenograft model. (A) Mice with established A431 tumors
received PBS (purple line), human IgG2 500 μg (blue line), panitumumab 5 μg (orange line), 20 μg (brown line), 200 μg (red line) or 500 μg (green
line) for 52 days. Mice were monitored continuously for 300 days after the last dose of panitumumab was administered. (B) Tumor inhibition
modeled data.
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internalization and degradation of the receptor [25,26].
Our data demonstrated similar reductions in the total
EGFR levels upon EGF stimulation (Figure 1A). In vivo,
two treatments with panitumumab were sufficient to sig-
nificantly inhibit EGFR autophosphorylation in the A431
cells growing as xenografts. Although detectable levels
of phosphorylated EGFR remained in the tumors, this
may be explained by an incomplete penetration of the
antibody at the 24-hour time point (see Figure 3A). The
significant inhibition of EGFR phosphorylation may also
suggest that EGF penetration is restricted to the perivas-
cular space at this early time point.Panitumumab serum concentrations from tumor-
bearing mice increased in a dose-proportional manner.
The trough levels in the xenograft bearing mice at a dose
of 200 μg were similar to those observed in the clinical
setting [21]. Using concurrent pharmacodynamic and
pharmacokinetic data, panitumumab penetration and
EGFR saturation in the tumors was measured. Barriers
to tumor penetration include high interstitial fluid pres-
sure and hydrostatic vascular pressure. Although these
potential pressures were not measured in this study,
panitumumab was able to penetrate the tumors. How-
ever, with the lower doses and at early time points, pene-
tration of panitumumab was restricted to regions of
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has been observed with other antibodies [2,27].
Consistent with the dose-dependent increase in serum
levels, panitumumab penetrated tumors in a dose- and
time-dependent manner. After 24 hours with the lowest
dose of 20 μg, panitumumab was detected in tumor
samples. Increasing panitumumab doses resulted in
increased tumor penetration to approximately 95% with
the highest dose of 500 μg 96 hours after the initial in-
jection. Although significant levels of panitumumab
bound to the EGFR on the tumor cell surface were mea-
sured at the single cell level at day 7 post treatment in
the receptor saturation assay (Figure 4B), there was
some variation between the results obtained with the
tumor penetration assay and the receptor saturation
assay at the earlier time points, which may reflect how
the total panitumumab was detected in each assay. The
tumor saturation assay only measures the level of pani-
tumumab on the cell surface and would not account for
receptor internalization as a result of panitumumab
treatment [28]. In addition, although significant effort
was made to minimize processing time, at the earlier
time points when panitumumab concentrations are
lower, the multiple processing steps for the tumor satur-
ation assay may wash off panitumumab versus immedi-
ate and direct fixation for the tumor penetration assay.
Panitumumab administration resulted in dose-dependent
tumor regression and eradication in this A431 xenograft
model, with animals remaining free of disease for 300 days
off treatment. Interestingly, 100% tumor eradication was
seen at a dose of 200 μg twice a week. The serum exposure
of panitumumab associated with these animals was similar
to those achieved in patients [21]. This association between
drug exposure that is achievable in the clinic and response
in preclinical models is different than that seen for some of
the small molecule EGFR inhibitors, which might explain
the lack of activity in settings that express only wild-type
EGFR [29,30].
Conclusions
These preclinical studies indicate that the pharmacoki-
netic and pharmacodynamic parameters of panitumu-
mab correlated with in vivo antitumor activity.
Furthermore, understanding these parameters may help
to understand the responses seen in patients receiving
panitumumab treatment.
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